Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion.

Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord.

HIV Med. 2018 Mar;19(3):184-194. doi: 10.1111/hiv.12567. Epub 2017 Dec 1.

2.

HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.

Soodla P, Simmons R, Huik K, Pauskar M, Jõgeda EL, Rajasaar H, Kallaste E, Maimets M, Avi R, Murphy G, Porter K, Lutsar I; Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord.

HIV Med. 2018 Jan;19(1):33-41. doi: 10.1111/hiv.12535. Epub 2017 Aug 1.

PMID:
28762652
3.

Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.

Olson AD, Walker AS, Suthar AB, Sabin C, Bucher HC, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):100-8. doi: 10.1097/QAI.0000000000001029.

4.

The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.

Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, Lutsar I, Chaix ML, Fisher M, Moreno S, Porter K; CASCADE Collaboration in EuroCoord.

AIDS. 2016 Mar 27;30(6):879-88. doi: 10.1097/QAD.0000000000000991.

5.

Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.

Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson AM, Kelleher AD, Morrison C, Thiebaut R, Wittkop L, Touloumi G; CASCADE Collaboration in EuroCoord.

Lancet HIV. 2014 Dec;1(3):e119-26. doi: 10.1016/S2352-3018(14)00002-2. Epub 2014 Nov 18.

PMID:
26424120
6.

Evaluation of rapid progressors in HIV infection as an extreme phenotype.

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240.

7.

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord.

Gastroenterology. 2013 Apr;144(4):751-760.e2. doi: 10.1053/j.gastro.2012.12.026. Epub 2012 Dec 22.

PMID:
23266560
8.

Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.

Clin Infect Dis. 2013 Mar;56(6):888-97. doi: 10.1093/cid/cis1000. Epub 2012 Dec 7.

PMID:
23223594
9.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
10.

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

Writing Committee for the CASCADE Collaboration.

Arch Intern Med. 2011 Sep 26;171(17):1560-9. doi: 10.1001/archinternmed.2011.401.

11.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Clin Infect Dis. 2011 Oct;53(8):817-25. doi: 10.1093/cid/cir494.

PMID:
21921225
12.

Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.

Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; CASCADE Collaboration.

AIDS. 2011 Jul 17;25(11):1395-403. doi: 10.1097/QAD.0b013e3283489c8b.

PMID:
21572307
13.

The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.

van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; CASCADE Collaboration.

AIDS. 2011 May 15;25(8):1083-91. doi: 10.1097/QAD.0b013e3283471cce.

PMID:
21537114
14.

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members.

PLoS Med. 2010 Feb 23;7(2):e1000239. doi: 10.1371/journal.pmed.1000239.

15.

Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.

Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NK, Jorgensen LB, de Mendoza C, Bhaskaran K, Gill ON, Johnson AM, Pillay D; Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) Collaboration.

J Infect Dis. 2009 Feb 1;199(3):427-31. doi: 10.1086/596049.

PMID:
19133810
16.

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.

Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):492-8. doi: 10.1097/QAI.0b013e318186ead2.

PMID:
18989233
17.

Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.

Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K; HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS); Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration.

J Infect Dis. 2008 Feb 1;197(3):398-404. doi: 10.1086/524686.

PMID:
18248303
18.

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K; CASCADE Collaboration.

Ann Neurol. 2008 Feb;63(2):213-21.

PMID:
17894380
19.

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.

Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):554-61.

PMID:
16868497
20.

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):505-11.

PMID:
16284524

Supplemental Content

Loading ...
Support Center